These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12551818)

  • 1. FLT3 inhibition as tailored therapy for acute myeloid leukemia.
    Martinelli G; Piccaluga PP; Lo Coco F
    Haematologica; 2003 Jan; 88(1):4-8. PubMed ID: 12551818
    [No Abstract]   [Full Text] [Related]  

  • 2. FLT3 Inhibitors in the Treatment of AML.
    Gilliland DG
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):708-10. PubMed ID: 16163256
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro activity of the flt3-inhibitor su5614 and standard cytotoxic agents in tumour cells from patients with wild type and mutated flt3 acute myeloid leukaemia.
    Aleskog A; Höglund M; Pettersson J; Hermansson M; Larsson R; Lindhagen E
    Leuk Res; 2005 Sep; 29(9):1079-81. PubMed ID: 16038735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
    Spiekermann K; Hiddemann W; Schnittger S
    Dtsch Med Wochenschr; 2005 Apr; 130(16):1020-5. PubMed ID: 15830315
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
    O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
    Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mutations in the FLT3 gene in adult patients with refractory acute myeloid leukemia.
    Choi Y; Kim HJ; Park BH; Min WS; Kim CC
    Leukemia; 2005 Jan; 19(1):141-3. PubMed ID: 15510198
    [No Abstract]   [Full Text] [Related]  

  • 7. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.
    Scholl S; Krause C; Loncarevic IF; Müller R; Kunert C; Wedding U; Sayer HG; Clement JH; Höffken K
    J Lab Clin Med; 2005 Jun; 145(6):295-304. PubMed ID: 15976757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplified capillary electrophoresis detection of the Flt-3 internal tandem duplications and D835 point mutations in acute myeloid leukemia.
    Chang TL; Salto-Tellez M; Kueh YK; Koay ES
    Haematologica; 2003 Feb; 88(2):ELT04. PubMed ID: 12604435
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of FLT3 in haematopoietic malignancies.
    Stirewalt DL; Radich JP
    Nat Rev Cancer; 2003 Sep; 3(9):650-65. PubMed ID: 12951584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 mutations in myeloid sarcoma.
    Ansari-Lari MA; Yang CF; Tinawi-Aljundi R; Cooper L; Long P; Allan RH; Borowitz MJ; Berg KD; Murphy KM
    Br J Haematol; 2004 Sep; 126(6):785-91. PubMed ID: 15352981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type.
    Chen W; Jones D; Medeiros LJ; Luthra R; Lin P
    Br J Haematol; 2005 Sep; 130(5):726-8. PubMed ID: 16115128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
    Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
    Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.
    Hunter HM; Pallis M; Seedhouse CH; Grundy M; Gray C; Russell NH
    Br J Haematol; 2004 Oct; 127(1):26-33. PubMed ID: 15384974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication.
    Muñoz L; Aventín A; Villamor N; Juncà J; Acebedo G; Domingo A; Rozman M; Torres JP; Tormo M; Nomdedéu JF
    Haematologica; 2003 Jun; 88(6):637-45. PubMed ID: 12801839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients.
    Andersson A; Johansson B; Lassen C; Mitelman F; Billström R; Fioretos T
    Eur J Haematol; 2004 May; 72(5):307-13. PubMed ID: 15059064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia.
    Moreno I; Martín G; Bolufer P; Barragán E; Rueda E; Román J; Fernández P; León P; Mena A; Cervera J; Torres A; Sanz MA
    Haematologica; 2003 Jan; 88(1):19-24. PubMed ID: 12551822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathophysiology and treatment of acute myeloid leukemia].
    Naoe J
    Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
    [No Abstract]   [Full Text] [Related]  

  • 19. FLT3: ITDoes matter in leukemia.
    Levis M; Small D
    Leukemia; 2003 Sep; 17(9):1738-52. PubMed ID: 12970773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT-3: a new focus in the understanding of acute leukemia.
    Markovic A; MacKenzie KL; Lock RB
    Int J Biochem Cell Biol; 2005 Jun; 37(6):1168-72. PubMed ID: 15778081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.